Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. - Tabular View

Tracking Information
First Received Date ^ICMJE	September 12, 2002
Last Updated Date	February 2, 2006
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00045864 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
Official Title ^ICMJE
Brief Summary	The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Lymphoma, Non-Hodgkin
Intervention ^ICMJE	Drug: Recombinant Human Interleukin-2 and Rituximab
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion: Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens. Exclusion: Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment Clinically significant pulmonary dysfunction. Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment). Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. History of autoimmune disease. History of positive serology for human immunodeficiency virus (HIV).
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00045864
Responsible Party
Study ID Numbers ^ICMJE	IL2NHL05
Study Sponsor ^ICMJE	Chiron Corporation
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Chiron Corporation
Verification Date	February 2006
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP